Role of AVP in maintenance of circulatory homeostasis during hemorrhagic shock.
Hemorrhagic hypotension produces significantly increased plasma arginine vasopression (AVP) concentrations. We have utilized a specific antagonist (AVP-A) of the pressor effects of endogenous AVP to investigate the role of this neurohypophyseal hormone on the pathogenesis of hemorrhagic shock. Infusion of the AVP-A (2 micrograms/kg bolus + 2 micrograms X kg-1 X h-1 infusion) into sham-shocked animals produced no significant changes in any of the observed experimental variables. Cats subjected to hemorrhagic shock given AVP-A had final superior mesenteric artery flow (SMAF) values significantly (P less than 0.05) higher than shock cats given vehicle (7.7 +/- 1.1 vs. 4.5 +/- 0.8 ml X kg-1 X min-1, respectively). Increases in postreinfusion plasma cathepsin D activities were significantly blunted in hemorrhaged animals treated with AVP-A (10.4 +/- 2.0 vs. 24.8 +/- 5.5 U/mg protein; P less than 0.05). Plasma proteolysis as well as the plasma accumulation of myocardial depressant factor (MDF) were also significantly modulated by AVP-A treatment in hemorrhaged animals. MDF activities were 75 +/- 6 and 53 +/- 4 U/ml (P less than 0.02) for shock cats given vehicle or AVP-A, respectively. However, these beneficial actions were not reflected in any significant improvement in postreinfusion mean arterial blood pressure (MABP). These findings suggest that endogenous AVP functions not only as a potent splanchnic vasoconstrictor but also as a key humoral factor in the maintenance of postreinfusion MABP, a profile that is different from the role of angiotensin II, the other major splanchnic vasoconstrictor, in shock.
D000818:Animals; D001127:Arginine Vasopressin / Q000031:analogs & derivatives / Q000502:physiology* / Q000627:therapeutic use; D001775:Blood Circulation; D001794:Blood Pressure; D002402:Cathepsin D; D002403:Cathepsins / Q000097:blood; D002415:Cats; D006706:Homeostasis; D066298:In Vitro Techniques; D008297:Male; D008638:Mesenteric Arteries; D009201:Myocardial Depressant Factor / Q000097:blood; D009584:Nitrogen / Q000097:blood; D012039:Regional Blood Flow; D012771:Shock, Hemorrhagic / Q000188:drug therapy / Q000503:physiopathology*; D013997:Time Factors
D009201:Myocardial Depressant Factor; D001127:Arginine Vasopressin; C025044:argipressin, beta-mercapto-beta,beta cyclopentamethylenepropionic acid(1)-; D002403:Cathepsins; D002402:Cathepsin D; D009584:Nitrogen